Biopharmaceuticals / Oncology / Protein Therapeutics
Strategic Profile
Founded in 2004 by researchers from the University of Zürich who discovered and developed the DARPin technology, the company leverages its proprietary platform for partnered development and internal programs. The company's focus is on advancing its clinical assets, with strong data emerging from MP0533 and MP0712.
Cyborg Score Rationale
The company completed a strategic workforce reduction of approximately 24% (40 positions) to extend cash runway into 2028. Positioned in a competitive oncology space with emerging clinical data, the company faces typical clinical-stage biotech risk but has backing from major pharma partnerships.
Top Insights
MP0712, a Radio-DARPin targeting DLL3, presented first encouraging human images at TRP Summit Europe and is being developed with strategic partner Orano Med for small cell lung cancer treatment
Clinical data from lead programs MP0533 and MP0712 expected in H2 2025
Since inception in 2004, Molecular Partners licensed DARPin candidates to leading pharmaceutical companies including Amgen, Roche and Janssen
Strategic restructuring extended cash runway from 2027 to 2028, supporting development of clinical assets
Named Competitors
Antibody-based therapeutics — Monoclonal antibodies and therapeutic proteins
Radio-labeled therapeutics — Targeted radiopharmaceuticals for cancer
Protein engineering platforms — Advanced protein and antibody technologies
Recent Developments
(November 2025) MP0712 Radio-DARPin presented first human imaging data showing targeted tumor delivery with limited organ exposure
(June 2025) Strategic workforce reduction of 40 positions to extend cash runway to 2028
(2024-2025) MP0533 and MP0712 advancing through clinical development with data expected in H2 2025
Open the full interactive Molecular Partners AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.